Untreated Chronic Hepatitis B Is Associated With a Higher Risk of Extrahepatic Malignancies.

Competing Interests: Lewis R. RobertsConsulting or Advisory Role: Bayer (Inst), GRAIL (Inst), RedHill Biopharma (Inst), TAVEC (Inst), Exact Sciences (Inst), QED Therapeutics (Inst), Biocompatibles (Inst), Hepion Pharmaceuticals (Inst), Novartis Venture Fund (Inst), Medscape (Inst), Roche Laboratories Inc (Inst), Focus Medical Communications (Inst), Global Life Science (Inst), Clinical Care Options (Inst), Lynx-Group (Inst), AstraZeneca (Inst), Genentech (Inst)Speakers' Bureau: BayerResearch Funding: ARIAD (Inst), BTG (Inst), Exact Sciences (Inst), Gilead Sciences (Inst), Wako Diagnostics (Inst), Glycotest (Inst), RedHill Biopharma (Inst)Patents, Royalties, Other Intellectual Property: US Patent No. 9,469,877: Materials and Methods for Diagnosis, Prognosis, Monitoring of Recurrence and Assessment of Therapeutic/Prophylactic Treatment of Pancreaticobiliary Cancer (Inst), Five Prime Therapeutics. Royalties, Five Prime Therapeutics. Royalties (Inst)Travel, Accommodations, Expenses: Gilead SciencesNo other potential conflicts of interest were reported.